Understanding how certain cells affect the immune response to brain tumors after radiation therapy
Official title: Role of FAP-positive cells in immune response to irradiated glioblastoma
Funded at Weill Medical Coll of Cornell Univ · NIH-10825590 · Data updated 2026-11-12
This study is looking at how certain cells in the body, called FAP+ cells, affect the immune system's response to glioblastoma, a tough brain tumor, to find better ways to make cancer treatments work after radiation therapy, and patients may be involved to help discover new treatment options.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Weill Medical Coll of Cornell Univ NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | April 10, 2023 |
| Project end | March 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $188,198 |
| NIH project number | 5R21CA280787-02 |
| Project ID | NIH-10825590 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults diagnosed with glioblastoma who are undergoing or have undergone radiation therapy.
✕Less likely to help
Patients with other types of brain tumors or those who are not receiving radiation therapy may not benefit from this research.
What this research studies
This research investigates the role of fibroblast activating protein-positive (FAP+) cells in the immune response to glioblastoma, a type of aggressive brain tumor. The study aims to understand how these cells contribute to the tumor's ability to resist treatment, particularly after radiation therapy. By examining the immune suppression caused by FAP+ cells, the researchers hope to identify new strategies to enhance the effectiveness of existing cancer therapies. Patients may be involved in this research to help uncover mechanisms that could lead to improved treatment outcomes.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for glioblastoma, potentially improving survival rates and quality of life for patients.
How similar studies have gone: While the role of FAP+ cells in other cancers has been studied, this specific investigation in glioblastoma is relatively novel and untested.
Where this research is happening
-
Weill Medical Coll of Cornell Univ
New York, United States Active
Researchers
- Principal investigator: Vanpouille-Box, Claire Isabelle — Weill Medical Coll of Cornell Univ
- Study coordinator: Vanpouille-Box, Claire Isabelle
Related research
Other NIH-funded projects on the same topics.
-
Small molecules to block Slit2/ROBO in glioblastoma
A study to test small molecule drugs that block Slit2/ROBO signals to help treat glioblastoma in patients.
-
Immunotherapy for glioblastoma: advancing treatment and understanding
A patient-friendly summary of a grant exploring new immune-based treatments for glioblastoma to improve options for people affected by this brain cancer.
-
Small-molecule and biologic treatments for glioblastoma using targeted brain delivery
A new approach aims to use FPS-ZM1 to shrink brain swelling and support immunotherapy for glioblastoma, potentially helping patients recover after surgery.
-
Targeted therapies for glioblastoma in adults and kids
A large NIH program is exploring new brain cancer therapies, including drugs that reach the brain and work against glioblastoma in both children and adults.
-
6-thio-2'-deoxyguanosine for glioblastoma: a new approach to target tumors before surgery
A trial tests a novel drug given before glioblastoma surgery to see how it behaves in the body and within the tumor, and to learn how it affects cancer cells and the immune environment.
-
CD38-Driven Changes in Brain Tumor Metabolism and Immunity in Glioblastoma
A patient-facing look at how scientists plan to study how glioblastoma grows by changing its metabolism and dampening the immune response, with potential targets to help treatment in the future.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.